Stock A314130 GENOME & COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genome & Company

Equities

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
6,910 KRW +2.98% Intraday chart for Genome & Company -1.71% -44.68%
Jan. 24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
2023 Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 323,319 1,048,465 468,827 245,897 176,209
Enterprise Value (EV) 1 300,094 940,636 398,490 145,490 116,390
P/E ratio -3.72 x -24.9 x -13.7 x -4.74 x -3.72 x
Yield - - - - -
Capitalization / Revenue 7,054 x 6,963 x 1,039 x 17.5 x 12.3 x
EV / Revenue 6,547 x 6,247 x 883 x 10.3 x 8.14 x
EV / EBITDA -22.6 x -37.4 x -11.9 x -3.03 x -2.49 x
EV / FCF - -12,258,438 x -23,263,737 x -4,118,887 x -3,699,967 x
FCF Yield - -0% -0% -0% -0%
Price to Book -7.94 x 9.49 x 5.26 x 2.55 x 2.98 x
Nbr of stocks (in thousands) 8,227 13,188 13,511 14,092 14,108
Reference price 2 39,300 79,500 34,700 17,450 12,490
Announcement Date 3/10/21 3/10/21 3/21/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 45.83 150.6 451.2 14,085 14,296
EBITDA 1 -13,251 -25,164 -33,496 -48,051 -46,820
EBIT 1 -13,821 -26,629 -36,087 -57,512 -55,092
Operating Margin -30,155.63% -17,683.84% -7,997.2% -408.34% -385.37%
Earnings before Tax (EBT) 1 -84,669 -31,186 -36,004 -58,033 -51,855
Net income 1 -84,669 -30,732 -34,117 -51,838 -47,466
Net margin -184,731.34% -20,409.23% -7,560.62% -368.05% -332.02%
EPS 2 -10,562 -3,192 -2,538 -3,683 -3,362
Free Cash Flow - -76,734 -17,129 -35,323 -31,457
FCF margin - -50,958.36% -3,795.98% -250.79% -220.04%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/10/21 3/10/21 3/21/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 23,225 107,829 70,338 100,408 59,819
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -76,734 -17,129 -35,323 -31,457
ROE (net income / shareholders' equity) - -80.9% -31.5% -43.2% -38.4%
ROA (Net income/ Total Assets) - -21.3% -17.5% -23.2% -20.6%
Assets 1 - 144,097 195,207 223,686 230,940
Book Value Per Share 2 -4,950 8,375 6,593 6,838 4,191
Cash Flow per Share 2 2,737 7,813 2,563 5,125 3,827
Capex 1 688 1,504 2,875 6,849 18,853
Capex / Sales 1,500.1% 999.1% 637.2% 48.63% 131.88%
Announcement Date 3/10/21 3/10/21 3/21/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENOME & COMPANY Stock Genome & Company
-44.68% 73.04M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A314130 Stock
  4. Financials Genome & Company